top of page
Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Mitoconix Bio | Biotechnology & Biopharmaceutical | 01/01/2016 | "1-10" |
Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.
The company’s lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntington’s disease and Parkinson’s disease, and it has shown beneficial activity in patient-derived cells of Huntington’s disease, sporadic and genetic Parkinson’s disease, and sporadic and genetic Alzheimer’s disease.
bottom of page